AIM
ABEO icon

Acrospire Investment Management’s Abeona Therapeutics ABEO Stock Holding History

Acrospire Investment Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-391
Closed -$47K – 2178
2016
Q4 		$47K Buy
391
+167
+75% +$26.1K 0.02% 1422
2016
Q3 		$34K Buy
224
+197
+730% +$19.3K 0.02% 1276
2016
Q2 		$2K Sell
27
-113
-81% -$7.72K ﹤0.01% 1939
2016
Q1 		$9K Buy
+140
New +$9.27K 0.01% 1761

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Acrospire Investment Management's ABEO Position: Q1 2017 in Review

Acrospire Investment Management sold out of Abeona Therapeutics (ABEO) in Q1 2017, closing a stake of 391 shares — an estimated $47K sold.

Acrospire Investment Management first reported a position in ABEO in Q1 2016 and held it in 4 quarters. The position peaked at $47K in Q4 2016. 58 funds tracked by Wall St. Rank hold ABEO as of Q1 2017.

  • Acrospire Investment Management reported no remaining Abeona Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 391 Abeona Therapeutics shares in Q1 2017, an estimated $47K.
  • Acrospire Investment Management first reported a position in Abeona Therapeutics in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Abeona Therapeutics position peaked at $47K in Q4 2016.
  • 58 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.